Low molecular weight heparins for venous thromboembolism

Drug and Therapeutics Bulletin

Volumn 36, Issue 4, 1998, Pages 25-29

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CERTOPARIN; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BLEEDING; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG USE; ERYTHEMA; HUMAN; LUNG EMBOLISM; ORTHOPEDIC SURGERY; OSTEOPOROSIS; PRURITUS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; URTICARIA;

EID: 0031954251     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.1998.36425     Document Type: Review

References (39)

1. Low-molecular-weight heparins in orthopaedic surgery. DTB 1993; 31. 37-8.
2. Barrowcliffe TW. Low molecular weight heparin(s). Br J Haematol 1995; 90: 1-7.
3. Thomas DP. Does low molecular weight heparin cause less bleeding? Thromb Haemost 1997; 78: 1422-5.
4. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
5. Bara L, Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl 1988; 543: 65-72.
6. Handeland GF, Abildgaard U, Holm HA, Arnesen K-E. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990; 39: 107-12.
7. Barrowcliffe TW, Curtis AD, Johnson EA, Thomas DP. An international standard for low molecular weight heparin. Thromb Haemost 1988; 60: 1-7.
8. Heilmann L. Kruck M, Schindler AE. Prevention of thrombosis in gynaecological surgery: a randomised double-blind study comparing low molecular weight heparin (LMWH) and unfractionated heparin (UFH). Geburish u Frauenheilk 1989; 49: 803-7.
9. Liezorovicz A, Picolet H, Peyrieux JC, Boissel JP and the HBPM Research Group. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg 1991; 78: 412-6.
10. Koppenhagen K, Adolf J, Matthes M et al. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb Haemost 1992; 67: 627-30.
11. Kakkar VV, Cohen AT, Edmondson RA et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-65.
12. Nurmohamed MT, Rosendaal FR, Bûller HR et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-6.
13. Leizorovicz A, Haugh MC, Chapuis F-R, Samama MM, Boissel J-P. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913-20.
14. Palmer AJ, Koppenhagen K, Kirchof B, Weber U, Bergemann R. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials. Haemostasis 1997; 27: 75-84.
15. Planes A, Vochelle N, Darmon J-Y, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancer 1996; 348: 224-8.
16. Bergqvist D, Benoni G, Björgell O et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
17. Dahl OE, Andreassen G, Müller C et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thromb Haemosi 1995; 73: 1094 [abstract 743].
18. Murray DW, Carr AJ, Bulstrode CJK. Pharmacological thromboprophylaxis and total hip replacement J Bone Joint Surg 1995; 77-B: 3-5.
19. Francis RM, Brenkel IJ. Survey of use of thromboprophylaxis for routine total hip replacement by British orthopaedic surgeons. Br J Hosp Med 1997; 57: 427-31.
20. Hull RD, Raskob GE, Pineo GF et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
21. Prandoni P, Lensing AWA, Büller HR et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis Lancet 1992; 339: 441-5.
22. Simonneau G, Charbonnier B, Decousus H et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993; 153: 1541-6.
23. Hirsh J, Siragusa S, Cosmi B, Ginsberg JS. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost 1995; 74: 360-3.
24. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep vein thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995; 155: 601-7.
25. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81.
26. Koopman MMW, Prandoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-7.
27. ten Cate JW, Büller HR, Gent M et al on behalf of The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-62.
28. Simonneau G, Sors H, Charbonnier B et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-9.
29. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989; 62: 940-4.
30. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular heparin. Blood 1991; 78: 2337-43.
31. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia; association of thrombotic complications with heparin-dependent IgG antibody that induced thromboxane synthesis and platelet aggregation. Lancet 1982; ii: 1246-8.
32. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
33. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995; 86: 1368-73.
34. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
35. Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost 1994; 72: 330-4.
36. Planes A, Vochelle N, Mazas F et al. Prevention of postoperative venous thrombosis: a randomised trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988; 60: 407-10.
37. Drummond M, Aristides M, Davies L, Forbes C Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994; 81: 1742-6.
38. Bonis LC, Lassen MR. Thromboprophylaxis with low molecular weight heparin after major orthopaedic surgery is cost effective. Drugs 1996; 52 (suppl 7): 42-6.
39. Valette F, Hoffmeyer U, Lloyd A. Economic evaluation of the use of tinzaparin in the treatment of deep vein thrombosis. Br J Med Econ 1995; 8: 111-23.